Bristol-Myers Squibb Company Ce (CELG-RI) Earnings History
Annual and quarterly earnings data from 1989 to 2025
Loading earnings history...
CELG-RI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CELG-RI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 65.9% | 31.4% | 14.6% |
| 2024 | 56.8% | 20.0% | -18.5% |
| 2023 | 76.2% | 18.2% | 17.8% |
| 2022 | 78.0% | 19.7% | 13.7% |
| 2021 | 78.6% | 18.4% | 15.1% |
Download Data
Export CELG-RI earnings history in CSV or JSON format
Free sign-in required to download data
Bristol-Myers Squibb Company Ce (CELG-RI) Earnings Overview
As of May 6, 2026, Bristol-Myers Squibb Company Ce (CELG-RI) reported trailing twelve-month net income of $7.28B, reflecting +178.5% year-over-year growth. The company earned $3.55 per diluted share over the past four quarters, with a net profit margin of 14.6%.
Looking at the long-term picture, CELG-RI's historical earnings data spans multiple years. The company achieved its highest annual net income of $10.61B in fiscal 2009.
Bristol-Myers Squibb Company Ce maintains positive profitability with a gross margin of 65.9%, operating margin of 31.4%, and net margin of 14.6%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including BMY ($7.28B net income, 14.6% margin), MRK ($18.25B net income, 28.1% margin), PFE ($7.49B net income, 12.4% margin), CELG-RI has outperformed on profitability metrics. Compare CELG-RI vs BMY →
CELG-RI Earnings vs Peers
Earnings metrics vs comparable public companies
CELG-RI Historical Earnings Data (1989–2025)
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.05B | +178.8% | $15.12B | $3.46 | 14.6% | 31.4% |
| 2024 | -$8.95B | -211.5% | $9.66B | $-4.41 | -18.5% | 20.0% |
| 2023 | $8.03B | +26.8% | $8.20B | $3.86 | 17.8% | 18.2% |
| 2022 | $6.33B | -9.5% | $9.10B | $2.95 | 13.7% | 19.7% |
| 2021 | $6.99B | +177.6% | $8.54B | $3.12 | 15.1% | 18.4% |
| 2020 | -$9.02B | -362.1% | $2.18B | $-3.98 | -21.2% | 5.1% |
| 2019 | $3.44B | -30.6% | $5.91B | $2.01 | 13.2% | 22.6% |
| 2018 | $4.95B | +391.8% | $5.12B | $3.03 | 21.9% | 22.7% |
| 2017 | $1.01B | -77.4% | $3.45B | $0.61 | 4.8% | 16.6% |
| 2016 | $4.46B | +174.4% | $4.54B | $2.65 | 22.9% | 23.4% |
See CELG-RI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CELG-RI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CELG-RI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCELG-RI — Frequently Asked Questions
Quick answers to the most common questions about buying CELG-RI stock.
Is CELG-RI growing earnings?
CELG-RI EPS is $3.55, with earnings growth accelerating to +178.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $7.3B.
What are CELG-RI's profit margins?
Bristol-Myers Squibb Company Ce net margin is +14.6%, with operating margin at +31.4%. Margins sit within typical range for the sector.
How consistent are CELG-RI's earnings?
CELG-RI earnings data spans 1989-2025. The accelerating earnings trend is +178.5% YoY. Historical data enables comparison across business cycles.